The detailed analysis of adenosquamous cancer of the pancreas (ASCP) suggested FGFR and RORC were two promising therapeutic targets.
List view / Grid view
Filter the results
A study has shown that inhibiting sortilin, a neuroprotein known to have increased expression in cancers, reduces pancreatic cancer invasiveness in vitro.
A protein called PPP1R1B has been revealed as a drug target for pancreatic cancer as it stopped the metastasis of tumours in mice.
Scientists identified a novel, highly specific drug target in the enzyme (sterol O-acyltransferase 1 (SOAT1)) cancer cells use to store cholesterol.
A study has shown that p53 rewires RNA splicing which leads to further activation of the KRAS oncogene, presenting a target for the progression of pancreatic cancer.
Exploring how therapies with multi-faceted approaches could improve options for treatment-refractory cancers, like pancreatic and triple-negative breast cancer.
By targeting NHE7 transport proteins in pancreatic tumours, researchers caused the pH of cancer cells to become acidic, combatting the condition.
Researchers have demonstrated that cysteinase, a new drug compound, can starve pancreatic cells of cysteine supply, causing ferroptosis.
Scientists identify innate lymphoid cells (ILCs) as possible targets for immunotherapies as their activation makes murine pancreatic tumours sensitive to PD-1 checkpoint inhibitors.
A team of scientists in the United States has successfully used a drug, which blocks AHR receptors, to prevent and treat obesity in mice. Their findings have spurred further research into the receptors’ association with diet and the gut microbiome.
Research indicates that activation of the RICTOR/mTORC2 pathway advances cancer metastasis and suggests that inhibiting this signalling may make chemotherapy more effective against colon cancer.
Researchers have discovered that pancreatic cancer cells secrete IL-1β to suppress the immune system and suggest antibody treatments as a therapy for pancreatic ductal adenocarcinoma.
Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.
A mechanism has been revealed that could be used to deny RAS mutant tumour cells (which is known to encourage the growth seen in pancreatic cancer patients) of a key survival mechanism.